| Prediction of drug combination effects with a minimal set of experiments A Ianevski, AK Giri, P Gautam, A Kononov, S Potdar, J Saarela, ... Nature machine intelligence 1 (12), 568-577, 2019 | 127 | 2019 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 92 | 2022 |
| Breeze: an integrated quality control and data analysis application for high-throughput drug screening S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ... Bioinformatics 36 (11), 3602-3604, 2020 | 89 | 2020 |
| Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä, ... BMC cancer 19, 1-14, 2019 | 69 | 2019 |
| ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors K Kaipio, P Chen, P Roering, K Huhtinen, P Mikkonen, P Östling, ... The Journal of pathology 250 (2), 159-169, 2020 | 45 | 2020 |
| Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data JP Mpindi, P Swapnil, B Dmitrii, S Jani, K Saeed, K Wennerberg, ... Bioinformatics 31 (23), 3815-3821, 2015 | 43 | 2015 |
| Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets S Adnan-Awad, D Kim, H Hohtari, KK Javarappa, T Brandstoetter, I Mayer, ... Leukemia 35 (7), 1964-1975, 2021 | 42 | 2021 |
| Human tumor–derived matrix improves the predictability of head and neck cancer drug testing K Tuomainen, A Al-Samadi, S Potdar, L Turunen, M Turunen, ... Cancers 12 (1), 92, 2019 | 34 | 2019 |
| Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas BA Brodin, K Wennerberg, E Lidbrink, O Brosjö, S Potdar, JN Wilson, ... British Journal of Cancer 120 (4), 435-443, 2019 | 34 | 2019 |
| Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment E Skaga, E Kulesskiy, M Brynjulvsen, CJ Sandberg, S Potdar, ... Clinical and translational medicine 8, 1-15, 2019 | 25 | 2019 |
| Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia BS White, SA Khan, MJ Mason, M Ammad-Ud-Din, S Potdar, D Malani, ... NPJ precision oncology 5 (1), 71, 2021 | 24 | 2021 |
| Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ... Oncotarget 8 (14), 22606, 2017 | 19 | 2017 |
| Targeting apoptosis pathways with BCL2 and MDM2 inhibitors in adult B-cell acute lymphoblastic leukemia H Hohtari, M Kankainen, S Adnan-Awad, B Yadav, S Potdar, A Ianevski, ... HemaSphere 6 (3), e701, 2022 | 11 | 2022 |
| High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma K Tuomainen, A Hyytiäinen, A Al-Samadi, P Ianevski, A Ianevski, S Potdar, ... Scientific Reports 11 (1), 14755, 2021 | 11 | 2021 |
| Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments SS Talwelkar, MI Mäyränpää, L Søraas, S Potdar, J Bao, A Hemmes, ... Cell Reports Medicine 2 (8), 2021 | 8 | 2021 |
| KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia D Malani, B Yadav, A Kumar, S Potdar, M Kontro, M Kankainen, ... Leukemia 34 (10), 2780-2784, 2020 | 8 | 2020 |
| Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers SS Talwelkar, AS Nagaraj, JR Devlin, A Hemmes, S Potdar, EA Kiss, ... Molecular cancer therapeutics 18 (10), 1863-1874, 2019 | 8 | 2019 |
| High miR-30 expression associates with improved breast cancer patient survival and treatment outcome M Jamshidi, R Fagerholm, TA Muranen, S Kaur, S Potdar, S Khan, E Netti, ... Cancers 13 (12), 2907, 2021 | 6 | 2021 |
| P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway Z Wang, M Mačáková, A Bugai, SG Kuznetsov, A Hassinen, T Lenasi, ... Nucleic acids research 51 (4), 1687-1706, 2023 | 5 | 2023 |
| BCR-ABL1 p190 in CML: a minor breakpoint with a major impact SA Awad, H Hohtari, KK Javarappa, T Brandstoetter, D Kim, S Potdar, ... Blood 134, 190, 2019 | 5 | 2019 |
Tero AittokallioUniversity of Helsinki, University of Turku, University of Oslo在 utu.fi 的电子邮件经过验证
